Biovica International AB Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
Sales 2024 * | 10M 950K 74.56M | Sales 2025 * | 116M 11.02M 865M | Capitalization | 202M 19.17M 1.5B |
---|---|---|---|---|---|
Net income 2024 * | -115M -10.93M -857M | Net income 2025 * | -60M -5.7M -447M | EV / Sales 2024 * | 12.8 x |
Net cash position 2024 * | 73.52M 6.99M 548M | Net cash position 2025 * | 45.95M 4.37M 343M | EV / Sales 2025 * | 1.34 x |
P/E ratio 2024 * |
-0.32
x | P/E ratio 2025 * |
-0.84
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.54% |
Latest transcript on Biovica International AB
Managers | Title | Age | Since |
---|---|---|---|
Anders Rylander
CEO | Chief Executive Officer | 54 | 31/12/09 |
Anders Morén
DFI | Director of Finance/CFO | 59 | 31/12/22 |
Hanna Ritzen
CTO | Chief Tech/Sci/R&D Officer | 45 | 31/12/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 64 | 19/03/19 | |
Annika Berg
BRD | Director/Board Member | 61 | 31/12/19 |
Maria Holmlund
BRD | Director/Board Member | 68 | 31/12/15 |
1st Jan change | Capi. | |
---|---|---|
-38.56% | 8.39B | |
+0.18% | 3.32B | |
+9.29% | 2.48B | |
-18.21% | 2.06B | |
-24.57% | 1.59B | |
+32.37% | 1.15B | |
-7.64% | 704M | |
+8.42% | 678M | |
-29.59% | 508M |